GHK-Cu — a copper tripeptide in research on the matrix and collagen

GHK-Cu is one of the best-characterised short copper peptides in the preclinical literature. The molecule is made up of three amino acids — glycine, histidine and lysine (Gly-His-Lys) — meaning it is a tripeptide that binds the copper(II) ion with very high affinity, forming the stable GHK-Cu complex. It is precisely this coordinated copper that gives solutions of the compound their characteristic blue colour. The GHK sequence is not an exotic molecule: it occurs as a fragment within the type I collagen chain, and in the body it appears, among other situations, during the remodelling of connective tissue. For this reason GHK-Cu has for decades been a subject of research on the extracellular matrix (ECM) and the biochemistry of collagen — as a model compound that makes it possible to observe how a short peptide can modulate cell behaviour in vitro.

Mechanism in brief

Unlike peptides that act through a single classic membrane receptor on a "key and lock" basis, GHK-Cu does not have one unambiguously identified receptor that would explain the whole body of observations. In the preclinical literature it is described rather as a molecule with multidirectional action: a carrier of bioavailable copper (an element that is a cofactor of many enzymes) and a modulator of gene expression. The copper bound in the complex takes part in reactions dependent on this metal, while the tripeptide itself has been studied as a factor influencing the transcriptional profile of fibroblasts. The precision of this type of molecule is sometimes described with the metaphor of "a screwdriver, not a hammer" — the point is narrowly defined biochemical pathways rather than a global stimulation of the cell.

What is the subject of research

The areas in which GHK-Cu appears in the literature are consistently assigned to specific models. The points below describe directions of research, not effects in humans.

• Collagen synthesis (in vitro). In cultures of human fibroblasts, increased expression and synthesis of collagen was observed, including type I collagen, as well as other matrix components such as glycosaminoglycans and decorin. This is the main thread of interest in the compound in the context of connective tissue biochemistry.
• Remodelling of the extracellular matrix (in vitro). The influence of GHK-Cu on the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) was studied — that is, on the system of enzymes responsible for remodelling the ECM. This is a model for analysing how a peptide can shift the degradation–rebuilding balance under laboratory conditions.
• Angiogenesis and the VEGF pathway (animal models and in vitro). Some preclinical works described a link between GHK-Cu and angiogenesis processes and VEGF signalling in tissue models. This area remains a subject of further verification.
• Modulation of gene expression (cell lines). Transcriptomic analyses in cell lines suggested that GHK-Cu may influence the activity of many genes at once, including those related to the antioxidant response and tissue remodelling. The scale and significance of these changes require further research.

Origin and historical context

The GHK peptide was isolated from human plasma and described in the early 1970s by Loren Pickart, whose work initiated the later interest in this sequence. The starting point was the observation that a plasma fraction containing GHK changed the behaviour of cells in culture. From a biochemical point of view, it is significant that the concentration of GHK in human plasma is highest in young adults and clearly decreases with age — this is a descriptive observation concerning physiology, not a premise for any applications in humans. It was precisely the combination of a simple structure, the presence of the sequence in collagen and the affinity for copper that made GHK-Cu one of the more frequently cited short peptides in research on the extracellular matrix.

Research specification

GHK-Cu is usually supplied as a lyophilisate (powder) of a blue colour, derived from the coordinated copper ion; after dissolution the solution retains this colour. The research material is stored under conditions appropriate for peptides in a laboratory context — away from light and moisture, in accordance with the batch documentation. The quality standard is purity determination by HPLC as well as identification and control of each batch; these parameters, together with physicochemical data, are found in the documentation available in the safety data sheets and COA section. It is worth noting that the GHK-Cu sequence circulates in trade in two distinct regulatory contexts: as an ingredient covered by cosmetic regulations (a form for external use) and as a research reagent in forms intended solely for laboratory applications. These are disjoint legal regimes — this description concerns exclusively the research context.

Level of evidence

Data concerning GHK-Cu come primarily from in vitro studies (fibroblast cultures, cell lines) and from animal models. Data from human studies are limited and do not allow conclusions to be drawn that go beyond the description of biochemical mechanisms observed under model conditions. Many of the described observations — from the influence on collagen synthesis to the modulation of gene expression — require further research, including replication and standardisation of methodology. GHK-Cu should therefore be regarded as an interesting object of basic research on the extracellular matrix, and not as a compound with an established profile of action in humans.

For research purposes only. Not for human or animal consumption. For research purposes only. Not for human or animal consumption.